Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD B GARON

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1134153745
CMS profile
50938
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$106,965.77

81 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $63,945.31 24
Travel and Lodging $41,555.75 29
Food and Beverage $1,464.71 28

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD B GARON

NPI 1134153745 · CMS profile ID 50938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD B GARON, NPI 1134153745, CMS profile ID 50938. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). EDWARD B GARON, NPI 1134153745, CMS profile ID 50938. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
EDWARD B GARON, NPI 1134153745, CMS profile ID 50938, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–81 of 81 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134153745?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

81 matching records · $106,965.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 81 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–81 of 81.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $23.1405/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225546899 CMS
Bayer Healthcare Pharmaceuticals Inc. $57.2405/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225546903 CMS
Bayer Healthcare Pharmaceuticals Inc. $170.4205/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225546905 CMS
Bayer Healthcare Pharmaceuticals Inc. $217.1005/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225546913 CMS
Bayer Healthcare Pharmaceuticals Inc. $35.1605/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225546917 CMS
Gilead Sciences, Inc. $2,910.0004/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351454 CMS
Gilead Sciences, Inc. $27.3804/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234373749 CMS
Gilead Sciences, Inc. $18.6904/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234374155 CMS
Merck Sharp & Dohme LLC $10,240.0004/07/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1237999110 CMS
Merck Sharp & Dohme LLC $150.0004/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238032328 CMS
Gilead Sciences, Inc. $489.3403/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234366001 CMS
Gilead Sciences, Inc. $48.5203/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234414550 CMS
Gilead Sciences, Inc. $14.0203/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234577327 CMS
Merck Sharp & Dohme LLC $27.2403/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237998490 CMS
Merck Sharp & Dohme LLC $13,326.7103/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238030036 CMS
Merck Sharp & Dohme LLC $47.1403/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238030258 CMS
Merck Sharp & Dohme LLC $218.0503/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238032874 CMS
Merck Sharp & Dohme LLC $36.6703/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238035870 CMS
Merck Sharp & Dohme LLC $217.2703/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1237996900 CMS
Merck Sharp & Dohme LLC $90.8903/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238032400 CMS
Regeneron Pharmaceuticals, Inc. $416.9703/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213238025 CMS
Regeneron Pharmaceuticals, Inc. $73.1703/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213238027 CMS
Regeneron Pharmaceuticals, Inc. $94.4503/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213238029 CMS
Regeneron Pharmaceuticals, Inc. $33.0303/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213238031 CMS
Regeneron Pharmaceuticals, Inc. $83.6903/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213238033 CMS
AstraZeneca Pharmaceuticals LP $3,280.0003/05/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206667291 CMS
Regeneron Pharmaceuticals, Inc. $172.9003/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213238023 CMS
Regeneron Pharmaceuticals, Inc. $185.9002/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1213238021 CMS
Merck Sharp & Dohme LLC $610.0002/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238007340 CMS
Merck Sharp & Dohme LLC $610.0002/17/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1238038750 CMS
ABBVIE INC. $2,537.5001/13/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1201904801 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $23,412.06 26
PY2020 $32,520.91 15
PY2021 $25,503.30 16
PY2022 $31,035.52 20
PY2023 $27,911.55 28
PY2024 $53,274.45 56
PY2025 $106,965.77 81

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $776,072.77 52
PY2024 Recipient $1,758.48 3
PY2024 Principal investigator $667,633.26 39
PY2023 Principal investigator $1,225,149.02 47
PY2022 Recipient $2,675.00 3
PY2022 Principal investigator $1,439,706.20 29
PY2021 Recipient $749.32 1
PY2021 Principal investigator $1,292,238.74 26
PY2020 Recipient $17,080.73 11
PY2020 Principal investigator $1,092,941.80 73
PY2019 Recipient $2,000.00 1
PY2019 Principal investigator $1,069,131.49 81

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,735.93 12/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations No dispute reported 06/30/2026 1232922836
Principal investigator 1 Merck Sharp & Dohme LLC $1,009.88 12/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects KEYNOTE-407 No dispute reported 06/30/2026 1232925781
Principal investigator 1 Merck Sharp & Dohme LLC $10,223.14 12/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- MK-3475, SCH 900475 Based Combination Therapy for Advanced Non-Small Cell Lung Cancer KEYNOTE-495 KeyImPaCT No dispute reported 06/30/2026 1232926051
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $12,869.00 12/22/2025 Non-covered Recipient Entity
The Regents Of The University Of California
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small No dispute reported 06/30/2026 1225414886
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $17,690.00 11/25/2025 Non-covered Recipient Entity
The Regents Of The University Of California
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small No dispute reported 06/30/2026 1225415422
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.20 10/16/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136743
Principal investigator 1 Daiichi Sankyo Inc. $1,110.60 10/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
U31402-A-U103 No dispute reported 06/30/2026 1223352962
Principal investigator 1 Daiichi Sankyo Inc. $45,375.56 09/25/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
U31402-A-U103 No dispute reported 06/30/2026 1223352960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,979.00 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,643.20 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,849.40 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,419.20 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,342.60 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136653
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.20 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $907.20 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,060.54 09/01/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136663
Principal investigator 1 Eli Lilly and Company $51,656.00 08/28/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS No dispute reported 06/30/2026 1187873281
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,326.00 07/21/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185554626
Principal investigator 1 Iovance Biotherapeutics, Inc. $12,410.00 07/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252498373
Principal investigator 1 Iovance Biotherapeutics, Inc. $24,820.00 07/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252498375
Principal investigator 1 Iovance Biotherapeutics, Inc. $22,338.00 07/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252498377
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,983.00 07/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252498379
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,892.00 07/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252498381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.00 06/19/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,525.00 06/19/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 06/19/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,292.00 06/19/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 =50% No dispute reported 06/30/2026 1184136605
Principal investigator 1 Eli Lilly and Company $11,172.40 06/05/2025 Covered Recipient Teaching Hospital
RONALD REAGAN UCLA
A PHASE 1 STUDY OF ORAL LOXO-260 IN PATIENTS WITH RET FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER, AND OTHER TUMORS WITH RET ACTIVATION REFRACTORY TO SELECTIVE RET INHIBITORS No dispute reported 06/30/2026 1187873279
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,914.00 06/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497071
Principal investigator 1 Iovance Biotherapeutics, Inc. $38,937.00 06/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497073
Principal investigator 1 Iovance Biotherapeutics, Inc. $408.00 06/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497075
Principal investigator 1 Iovance Biotherapeutics, Inc. $61,048.00 06/05/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497077
Principal investigator 1 Daiichi Sankyo Inc. $2,520.00 05/28/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
U31402-A-U103 No dispute reported 06/30/2026 1223352958
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $55,646.00 05/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1236000300
Principal investigator 1 Daiichi Sankyo Inc. $25,854.30 05/22/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
U31402-A-U103 No dispute reported 06/30/2026 1223352956
Principal investigator 1 Iovance Biotherapeutics, Inc. $534.00 05/22/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497063
Principal investigator 1 Iovance Biotherapeutics, Inc. $7,182.00 05/22/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497067
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,260.00 05/22/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497069
Principal investigator 1 Merck Sharp & Dohme LLC $8,185.00 05/21/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Randomized Double-Blind, Phase III Study of PlatinumPemtrexed Chemotherapy with or without Pembrolizumab MK-3475 in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects KEYNOTE-189 No dispute reported 06/30/2026 1232925847
Principal investigator 1 Iovance Biotherapeutics, Inc. $180.00 05/15/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497065
Principal investigator 1 Merck Sharp & Dohme LLC $41,400.00 05/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 1 Open-Label, Dose-escalated Trial of Tumor Necrosis Factor Alpha and Interleukin-2 coding Oncolytic Adenovirus TILT-123 in Combination with Pembrolizumab in Patients with Immune Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1232932171
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,852.10 04/17/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497061
Principal investigator 1 Genentech, Inc. $13,000.00 03/20/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211554600
Principal investigator 1 Iovance Biotherapeutics, Inc. $360.00 03/20/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497051
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,829.00 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497053
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,895.00 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497055
Principal investigator 1 Iovance Biotherapeutics, Inc. $8,983.00 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497057
Principal investigator 1 Iovance Biotherapeutics, Inc. $17,490.00 03/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
81990 No dispute reported 06/30/2026 1252497059
Principal investigator 1 Daiichi Sankyo Inc. $23,771.70 02/20/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
U31402-A-U103 No dispute reported 06/30/2026 1223352952
Principal investigator 1 Mirati Therapeutics, Inc. $124,643.86 02/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2 No dispute reported 06/30/2026 1236529976
Principal investigator 1 Daiichi Sankyo Inc. $15,708.00 02/06/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
U31402-A-U103 No dispute reported 06/30/2026 1223352954
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,598.76 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1236000298